The Ensign Group, Inc.

The Ensign Group, Inc. (ENSG) Market Cap

The Ensign Group, Inc. has a market capitalization of $10.38B.

Price: $178.16

-0.67 (-0.37%)

Market Cap: 10.38B

NASDAQ · time unavailable

CEO: Barry R. Port

Sector: Healthcare

Industry: Medical - Care Facilities

IPO Date: 2007-11-09

Website: https://ensigngroup.net

The Ensign Group, Inc. (ENSG) - Company Information

Market Cap: 10.38B|Sector: Healthcare

Company Profile

The Ensign Group, Inc. operates as a healthcare provider, primarily concentrating on post-acute care services, alongside other supporting business ventures. The company's activities are organized into two main divisions: Skilled Services and Real Estate. Within its Skilled Services segment, Ensign provides extensive short-term and long-term nursing care tailored for patients recovering from extended illnesses, managing chronic health conditions, or requiring elder care. This division also encompasses a variety of rehabilitative therapies, such as physical, occupational, and speech therapy, among other specialized healthcare provisions. Beyond direct medical care, the company furnishes essential amenities like lodging, customized dietary programs, and opportunities for social engagement, recreation, and entertainment. Ensign additionally manages senior living facilities and delivers convenient mobile diagnostic services. Its diverse array of supplementary services includes digital X-rays, ultrasounds, electrocardiograms, laboratory analyses, sub-acute care, and patient transportation, which can be provided either in patients' residences or at long-term care facilities. The company also engages in the leasing of real estate properties. As of April 4, 2022, Ensign operated a network of 252 healthcare facilities spread across thirteen U.S. states: Arizona, California, Colorado, Idaho, Iowa, Kansas, Nebraska, Nevada, South Carolina, Texas, Utah, Washington, and Wisconsin. The Ensign Group, Inc. was established in 1999 and is headquartered in San Juan Capistrano, California.

Analyst Sentiment

80%
Strong Buy

From 5 Active Polls

1Y Forecast: $220.00

▲ +23.5% Potential Upside

Consensus Target Metrics

Low Bound

$202

Median

$228

High Bound

$230

Average

$220

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$220.00
▲ +23.48% Upside
Low Target
$202.00
13% Risk
Median Target
$228.00
28% Mid
High Target
$230.00
29% Max
Consensus
Buy
9 / 13 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Period EndingTrailing 12MJun 30, 2026Mar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024
Market Cap ($M)10,3849,29111,64110,0309,9148,8177,3897,5678,166
Enterprise Value ($M)12,37211,27913,34613,68211,62710,4939,1159,0779,652
Price to Earnings Ratio (P/E)27.1223.3029.1226.2329.5826.0622.9423.7326.05
Price/Earnings-to-Growth Ratio (PEG)6.3113.875.305.295.596.375.085.94
Price to Sales Ratio (P/S)1.896.458.387.377.657.186.306.687.55
Price to Book Ratio (P/B)4.233.814.924.494.684.373.834.124.67
Price to Free Cash Flow Ratio (P/FCF)24.7877.99179.9775.1597.3883.07252.22144.7191.71
Enterprise Value to Sales (EV/Sales)7.839.6110.068.978.557.778.028.92
Enterprise Value to EBITDA (EV/EBITDA)19.9167.5383.7885.6485.9974.8668.6369.5479.00
Debt to Equity Ratio3.200.920.951.861.021.011.041.071.15

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ENSIGN GROUP INC (ENSG) — Investment Overview

🧩 Business Model Overview

Ensign Group operates skilled nursing facilities (and related post-acute senior care services) that generate revenue by caring for patients requiring longer-term skilled medical support, therapy, and nursing. The operating model is facility-based: Ensign recruits and manages clinical and non-clinical labor, maintains compliance with federal and state healthcare regulations, and supports patient intake and ongoing care delivery. Its economics are driven by how efficiently it staffs facilities, manages payer mix (including Medicaid and Medicare), sustains occupancy, and achieves quality outcomes that affect reimbursement and referrals.

💰 Revenue Streams & Monetisation Model

Revenue is primarily earned through reimbursement for patient care services. Monetisation is largely payer-driven (government and other payers) and tends to be “operating-margins sensitive” rather than purely volume-driven. Margin architecture typically depends on:

  • Payer mix and reimbursement rates: Medicaid and Medicare reimbursement levels and facility-level cost structures determine gross margin.
  • Occupancy/utilization: Higher utilization spreads fixed facility costs over more patient days.
  • Labor efficiency: Staffing models, nurse-to-patient requirements, and turnover management influence direct cost per patient day.
  • Ancillary services and therapy intensity: Therapy utilization and care plan intensity can support revenue per patient day when aligned with need.

Because skilled nursing is a regulated service line, revenue is not easily “productized” for recurring subscription economics; however, revenue streams are operationally repeatable via day-to-day patient care demand and facility-level capacity.

🧠 Competitive Advantages & Market Positioning

Ensign’s competitive positioning is less about proprietary technology and more about execution in a labor-intensive, regulation-heavy service business. The durable advantages are primarily operational know-how and cost-and-quality discipline, which function as a practical moat in skilled nursing.

  • Cost advantage through operational scale and labor management (moat-type: Cost Advantages): Facility networks allow better procurement, management staffing, and deployment of experienced operations leadership. In a business where labor is the dominant cost, operational routines that reduce turnover and improve scheduling efficiency can translate into sustained per-patient-day margin advantages.
  • Quality and compliance discipline (moat-type: Regulatory Moats / Intangible Assets): Skilled nursing providers face ongoing inspection, documentation, and outcomes requirements. Consistent compliance and quality performance can reduce adverse regulatory events and support patient flow and payer confidence.
  • Facility-level stickiness (moat-type: Switching Costs—limited but real): Patients and families typically face practical constraints (proximity, clinical readiness, caregiver planning). Once a facility becomes the care setting for a given episode of care, care transitions are not frictionless, creating some continuity for established operators.

Competitive benchmarking:

  • Brookdale Senior Living and Five Star Quality Care compete across senior living and skilled-related care categories with broader geographic and product exposure, often facing more variation in facility-level performance and mix.
  • Genesis Healthcare is a prominent skilled nursing competitor that has historically competed on scale and operating capability across post-acute settings.

Ensign’s industry focus emphasizes skilled nursing operations with concentrated regional footprint and disciplined execution—prioritizing predictable operations and staffing reliability versus pursuing broad product diversification. That focus tends to reinforce operational consistency, which is critical in environments where reimbursement and compliance standards tightly constrain margins.

🚀 Multi-Year Growth Drivers

  • Demographic tailwinds for post-acute and long-term care: Aging populations increase demand for skilled nursing and therapy services, expanding the addressable patient base over a multi-year horizon.
  • Continuing shift toward value and outcomes: Payers increasingly emphasize clinical outcomes, documentation quality, and effective care coordination. Operators that maintain compliance and staffing stability can benefit as performance expectations rise.
  • Industry consolidation and scale benefits: Financial pressure on smaller operators can accelerate consolidation. Larger, better-run networks often acquire or build facilities with more consistent execution, improving long-run throughput.
  • Labor availability and productivity as a secular differentiator: Over time, investors can underwrite incremental margin improvements where management systems lower turnover and improve staffing ratios, provided reimbursement does not compress faster than operational gains.

⚠ Risk Factors to Monitor

  • Reimbursement and policy risk: Changes to Medicare and Medicaid reimbursement methodologies, eligibility rules, or compliance documentation requirements can compress margins or alter patient volumes.
  • Wage inflation and staffing shortages: Skilled nursing economics remain highly sensitive to labor costs (nursing, therapy, and supportive staff). Inability to attract and retain staff can lead to margin erosion or quality issues.
  • Regulatory and survey outcomes: Enforcement actions, citations, staffing deficiencies, or quality penalties can impair revenue and increase operating costs.
  • Facility-level concentration and integration risk: Growth through acquisitions or new builds can bring variability in patient mix, operating history, and improvement timelines.
  • Liquidity and capital intensity: Facility maintenance, compliance remediation, and working capital needs can require consistent funding, particularly in periods of reimbursement pressure.

📊 Valuation & Market View

The market typically prices skilled nursing operators using EV/EBITDA and cash flow-based frameworks, reflecting the service-based, facility operating model. Key valuation drivers include:

  • Normalized same-facility margins (labor efficiency, utilization, and cost control).
  • Quality indicators and compliance stability that influence both reimbursement and regulatory exposure.
  • Durability of payer mix, including Medicaid reliance and any policy-driven shifts.
  • Leverage and interest-rate sensitivity, given ongoing capital and working capital needs.

Multiple expansion tends to correlate with credible evidence of sustained margin resilience and execution credibility across facility cycles, while multiple compression often follows policy uncertainty or evidence of persistent staffing and cost pressure.

🔍 Investment Takeaway

Ensign Group’s long-term investment case rests on earning power from disciplined skilled nursing operations: operational scale applied to labor and cost management, sustained regulatory compliance, and facility-level continuity that creates practical stickiness for patient care episodes. The business is exposed to reimbursement and staffing risks, but the primary differentiator remains execution quality—where operational systems can convert demographic demand into durable cash flows across the facility portfolio.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for ENSG.

zacks.com2026-07-31

Here's Why Ensign Group (ENSG) is a Strong Value Stock

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

newsfilecorp.com2026-07-31

Kaplan Fox Notifies The Ensign Group, Inc. (ENSG) Investors of a Securities Investigation into the Company

New York, New York--(Newsfile Corp. - July 31, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against The Ensign Group, Inc. ("Ensign" or the "Company") (NASDAQ: ENSG). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Ensign investor and have suffered losses, or if you have information that could assist in the Ensign investigation, you may CLICK HERE to contact us.

globenewswire.com2026-07-30

Ensign Investor News: If You Have Suffered Losses in The Ensign Group, Inc. (NASDAQ: ENSG), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

NEW YORK, July 30, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public. SO WHAT: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

zacks.com2026-07-30

ENSG Q2 Earnings Beat Estimates on Growing Occupancy, '26 View Raised

Ensign Group beats Q2 earnings and raises its 2026 outlook as higher occupancy, patient days and acquired facilities drive revenue growth.

seekingalpha.com2026-07-29

The Ensign Group, Inc. (ENSG) Q2 2026 Earnings Call Transcript

The Ensign Group, Inc. (ENSG) Q2 2026 Earnings Call Transcript

marketbeat.com2026-07-29

The Ensign Group Q2 Earnings Call Highlights

The Ensign Group NASDAQ: ENSG raised its 2026 earnings and revenue outlook after reporting second-quarter gains in revenue, earnings and occupancy, while highlighting continued acquisition activity and clinical quality measures across its skilled nursing portfolio.

newsfilecorp.com2026-07-29

Kaplan Fox is Investigating The Ensign Group, Inc. (ENSG) and Encourages Investors Who Suffered Losses to Contact the Firm

New York, New York--(Newsfile Corp. - July 29, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against The Ensign Group, Inc. ("Ensign" or the "Company") (NASDAQ: ENSG). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Ensign investor and have suffered losses, or if you have information that could assist in the Ensign investigation, you may CLICK HERE to contact us.

globenewswire.com2026-07-29

ENSG INVESTIGATION: Ensign Securities Fraud Investigation into Regulatory Issues is Ongoing – Contact BFA Law if You Lost Money

NEW YORK, July 29, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm  Bleichmar Fonti & Auld LLP announces an investigation into The Ensign Group, Inc. (NASDAQ:ENSG) for potential securities fraud after significant stock drops. If you invested in Ensign, you are encouraged to obtain additional information by visiting: https://www.bfalaw.com/cases/ensign-class-action-lawsuit.

prnewswire.com2026-07-28

Rosen Law Firm Encourages The Ensign Group, Inc. Investors to Inquire About Securities Class Action Investigation - ENSG

NEW YORK, July 28, 2026 /PRNewswire/ -- Why: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of The Ensign Group, Inc. (NASDAQ: ENSG) resulting from allegations that Ensign may have issued materially misleading business information to the investing public. So What: If you purchased Ensign securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.

globenewswire.com2026-07-27

Ensign 投資者消息:若您因 The Ensign Group, Inc. (NASDAQ: ENSG) 蒙受損失,請聯絡 Rosen Law Firm 了解您的權益

紐約, July 28, 2026 (GLOBE NEWSWIRE) -- 事因:全球投資者權益律師事務所 Rosen Law Firm 繼續代表 The Ensign Group, Inc. (NASDAQ: ENSG) 的股東,調查 Ensign 可能向投資公眾發佈重大誤導性業務資訊並就此引發的潛在證券索賠。 影響:如果您購買了 Ensign 證券,您可能有權獲得賠償,並透過勝訴收費安排,免去任何自付費用或開支。Rosen Law Firm 正準備提出集體訴訟,期望為投資者討回損失。 下一步行動:如欲加入潛在集體訴訟,請造訪 https://rosenlegal. com/cases/the-ensign-group-inc/join 或免費致電 866-767-3653 或電郵至 case@rosenlegal. com 與 Phillip Kim 律師聯絡,了解關於此集體訴訟的資訊。 事件概覽:2026 年 6 月 8 日,Investing. com 發佈了一則題為「Ensign Group 股價遭沽空報告拖累急挫」的報道。文章提到,Ensign 股價下跌是由於「沽空機構 Hunterbrook 發表報告,指稱該養老院營運商的經營模式實質上是依靠削減病人護理質素及玩弄質素評分。」 此外,文章提到,Hunterbrook「發佈了一項為期五個月的調查結果,指公司盈利來自院舍人手短缺,並把納稅人的金錢撥給高層及相關人士。報告指控有病人因此受苦,甚至喪生。」 在上述消息傳出後,Ensign Group 股價在 2026 年 6 月 8 日下跌 8.

newsfilecorp.com2026-07-27

Kaplan Fox & Kilsheimer LLP Announces an Investigation into The Ensign Group, Inc. (ENSG) for Possible Securities Law Violations

New York, New York--(Newsfile Corp. - July 27, 2026) - Kaplan Fox & Kilsheimer LLP is investigating potential securities violations against The Ensign Group, Inc. ("Ensign" or the "Company") (NASDAQ: ENSG). CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION If you are an Ensign investor and have suffered losses, or if you have information that could assist in the Ensign investigation, you may CLICK HERE to contact us.

benzinga.com2026-07-27

Ensign Signals Confidence with Higher 2026 Outlook after Solid Quarter

Ensign Group Inc. (NASDAQ:ENSG) stock is trading up after the company reported better-than-expected second-quarter earnings and raised fiscal 2026 estimates.

zacks.com2026-07-27

Here's What Key Metrics Tell Us About Ensign Group (ENSG) Q2 Earnings

Although the revenue and EPS for Ensign Group (ENSG) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com2026-07-27

Ensign Group (ENSG) Q2 Earnings and Revenues Top Estimates

Ensign Group (ENSG) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.8 per share. This compares to earnings of $1.59 per share a year ago.

globenewswire.com2026-07-27

The Ensign Group Reports Second Quarter 2026 Results

Raises 2026 Annual Earnings and Revenue Guidance; Conference Call and Webcast scheduled for July 29, 2026 at 10:00 am PT

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-06-30

"ENSG (most recent: 2026-06-30, Q2) reported Revenue of $1.440B and Net Income of $99.7M (EPS $1.72). QoQ, Revenue rose to $1.440B from $1.389B in Q1 (+3.7%), and Net Income was essentially flat at $99.7M vs. $99.7M (+0.1%). YoY, Revenue increased from $1.228B in Q2’25 to $1.440B (+17.3%), while Net Income grew from $84.4M to $99.7M (+18.2%), indicating operating leverage. Profitability is stable to slightly better: gross margin ticked up from 0.162 (Q2’25) to 0.166 (Q2’26), and net margin improved from 6.87% (Q2’25) to 6.92% (Q2’26). However, there’s mild margin volatility across quarters (e.g., Q4’25 gross margin was notably lower), so the current expansion looks incremental rather than step-change. Cash flow quality appears solid for a mature business: operating cash flow was $172.0M in Q2’26, translating to free cash flow of $119.1M. The company repurchased stock (-$41.0M) while paying modest dividends (-$3.8M), supporting shareholder yield. Total shareholder returns look strong: the stock is up +56.1% over 1 year, well above the 20% momentum threshold, which materially lifts the total return score. With valuation multiples implied by price/earnings (~23x) and price/free cash flow very high, analyst expectations (per consensus target $218 vs. ~$200) suggest upside is present but not aggressive."

Revenue Growth

Strong

QoQ Revenue +3.7% (Q1’26 $1.389B → Q2’26 $1.440B). YoY Revenue +17.3% (Q2’25 $1.228B → Q2’26 $1.440B), showing a clear upward trajectory.

Profitability

Good

Net Income YoY +18.2% with Net margin slightly higher YoY (6.87% → 6.92%). QoQ Net Income was flat (+0.1%). Margins are generally stable with modest improvement, not a dramatic expansion.

Cash Flow Quality

Good

Operating cash flow $172.0M in Q2’26 and free cash flow $119.1M. Shareholder cash deployment favors buybacks (-$41.0M) with small dividends (-$3.8M), consistent with coverage/payout ratio (~3.8% of payout metrics provided).

Leverage & Balance Sheet

Positive

Total assets increased to $5.75B (from $5.61B QoQ). Leverage remains meaningful with total debt ~$2.25B and net debt ~$1.99B; equity is stable around $2.44B. No bank-like asset risk profile, but debt/lease obligations are sizable.

Shareholder Returns

Strong

1-year price momentum is strong (+56.1%), exceeding the >20% threshold and indicating strong total return dynamics. Dividend yield is very low, but buybacks in the quarter support capital returns.

Analyst Sentiment & Valuation

Neutral

Consensus price target ~$218 vs. current ~$200 implies moderate upside. Valuation appears rich on earnings/FCF multiples (P/E ~23x; P/FCF very high per provided ratios), tempering the score despite positive sentiment.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Ensign delivered strong Q1 2026 operating momentum with record occupancy (84.3% same-store; 85.1% transitioning) and continued skilled-mix improvement (skilled revenue +9.6% and days +5.1% YoY; Medicare revenue +9.8% and +9.2%). Financial results confirmed the operating trend: GAAP diluted EPS of $1.67 (+21.9%) and adjusted diluted EPS of $1.85 (+21.7%), on revenue growth of 18.4% to $1.4B. Management raised full-year 2026 guidance to EPS $7.48–$7.62 and revenue $5.81B–$5.86B, citing strength in Q1, continued execution, and CMS 2027 net market basket uplift of 2.4%. The key debate in Q&A—clinical review intensity, managed care scrutiny, and M&A versus organic contribution—was addressed with consistent arguments: reviews are long-standing and are already operationalized through dedicated documentation teams, while turnaround deals can increase revenue disproportionately to EPS in the near term.

AI IconGrowth Catalysts

  • Same-store transitioning occupancy record highs: 84.3% (same-store) and 85.1% (transitioning)
  • Skilled mix momentum: same-store transitioning skilled revenue and days up 9.6% and 5.1% YoY; Medicare revenue up 9.8% and 9.2% (respectively skilled revenue and days)
  • Continued shift to higher acuity admissions supporting skilled nursing utilization despite clinical review scrutiny
  • Organic runway at 84% occupancy with mature operations often mid-90% occupancy

Business Development

  • Added 22 new operations during the quarter (21 real estate assets) and 71 operations acquired during 2025 and since
  • Geographic additions: 20 in Texas, 1 in Arizona, 1 in Wisconsin
  • Replacement construction completed: Grossmont Post-acute (La Mesa, CA) next to Sharp Grossmont Hospital; moved to a new state-of-the-art building and added 15 beds to reach 105 beds; skilled daily census increased from ~72 to 95 in months
  • Standard Bearer Healthcare REIT expanded: 21 new assets added during the quarter and since; Standard Bearer now 173 owned properties (137 leased to Ensign affiliates; 37 to third parties)
  • Standard Bearer rental revenue: $36.1M for the quarter; $30.8M from Ensign affiliated operations; EBITDAR-to-rent coverage 2.7x

AI IconFinancial Highlights

  • GAAP diluted EPS: $1.67 (+21.9% YoY); Adjusted diluted EPS: $1.85 (+21.7% YoY)
  • GAAP revenue and adjusted revenues both $1.4B (+18.4% YoY)
  • GAAP net income: $99.7M (+24.2% YoY); Adjusted net income: $110.2M (+23.9% YoY)
  • Cash and cash equivalents: $539.5M; cash flow from operations: $100.2M
  • Spent >$60M in the first 3 months of 2026 for strategic growth; lease-adjusted net debt-to-EBITDA: 1.73x after investments
  • CMS proposed 2027 SNF rule: net market basket increase of 2.4% referenced as reimbursement stability consistent with guidance
  • 2026 guidance raised: earnings $7.48–$7.62 per diluted share (from $7.41–$7.61); revenue $5.81B–$5.86B (from $5.77B–$5.84B)

AI IconCapital Funding

  • Quarterly cash dividends: $0.065/share
  • Line of credit: >$592M available capacity; combined cash + capacity implies over $1B dry powder
  • Lease-adjusted net debt-to-EBITDA: 1.73x after strategic growth investments
  • 179 assets owned; 155 owned completely debt-free (liquidity/collateral value referenced as supporting growth capacity)

AI IconStrategy & Ops

  • Accelerated growth: added 2,662 skilled nursing beds, 100 senior living units, and 55 independent living units across 3 states
  • Newly acquired group equals 17.4% of total portfolio
  • Transition model: decentralized, local cluster-driven approach to transitions; emphasis on breaking larger portfolios into bite-size pieces (3–4 buildings per cluster market vs large 20-building structures)
  • Labor execution: improved overtime management, agency spending, and turnover attributed to better real-time data visibility plus clustered CEO/COO-caliber leadership accountability; service center provides macro tools
  • Agency staffing reduced despite increased occupancy (as stated in prepared remarks)

AI IconMarket Outlook

  • 2026 guidance range: EPS $7.48–$7.62; revenue $5.81B–$5.86B
  • Guidance assumptions include ~60M diluted weighted average common shares, tax rate 25%, and inclusion of acquisitions closed/expected through 2Q26
  • CMS 2027 rule: referenced 2.4% net market basket increase (early April release) as consistent with guidance framework

AI IconRisks & Headwinds

  • Potential skepticism around managed care and clinical review intensity; management stated it is embedded/long-standing and does not translate into broad demand slowdown
  • Seasonality and variability factors explicitly noted for quarterly performance: reimbursement system variation, state budget delays/changes, seasonality in occupancy/skilled mix, general economy influences, census/staffing, insurance accrual variation
  • Acquisition-related short-term impact and system implementation costs (noted as guidance exclusions via stock-based compensation and system implementation costs)

Q&A: Analyst Interest

  • Clinical review intensity and whether managed care margin focus leads to more scrutiny: Management said clinical reviews are embedded and long-standing, backed by a dedicated analysis/documentation team for inquiries. They cited strong record occupancy and sequential increases in managed care and Medicare census from Q4 to Q1, arguing recent commentary doesn’t translate into business slowdown.
  • Bridge for EPS guidance raise vs M&A contribution: Management explained that turnaround acquisitions can drive revenue faster than EPS, so EPS impact lags revenue. They attributed the guidance raise mainly to strong Q1 execution and ongoing execution, not conservatism, noting seasonality through summer months and cost/revenue seasonality.
  • Deal pipeline composition and real estate angle: Management said pipeline trends show more midsized regional portfolios coming to market. They emphasized evolving approach versus earlier large “Legend” style deals by breaking large acquisitions into cluster-based bite-size transitions. For real estate, they said not necessarily more lease opportunities, but they prefer owning/operating first, then attractive long-term leases, and third-party leasing as needed.

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the ENSG Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for ENSG.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (ENSG)

© 2026 Stock Market Info — The Ensign Group, Inc. (ENSG) Financial Profile